课题基金 / 基金详情

Development of diagnostic tools and treatment based on the specific immune responses of VKH disease

Development of diagnostic tools and treatment based on the specific immune responses of VKH disease
基于 VKH 疾病特异性免疫反应开发诊断工具和治疗方法
批准号:
18591939
负责人:
YAMAKI Kunhiko
金额:
$2.31万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
为了建立诊断VKH病的可靠实验室检查方法,我们研究了VKH病特异性T细胞受体(TCR)。针对VKH的TCR库,我们制备了VKH特异性TCR库抗原,但目前还难以获得VKH特异性TCR抗体,也难以建立VKH特异性调节性树突状细胞。眼内组织中存在多种摄取多肽抗原的细胞。这些细胞可分为3 ~ 4组,这些细胞组具有不同的细胞表面标志,可能发挥不同的功能。在脉络膜组织中,这些细胞可以作为刺激T细胞的APC发挥作用,而在视网膜中,这些细胞可以作为调节T细胞/T细胞的APC发挥作用。
英文摘要
To develop the reliable laboratory examination for diagnosis of VKH disease, we studied the T cell receptors (TCRs) specific for VKH disease. The antigens were raised against the TCR pools specific for VKH.It was difficult to get the antibodies specific against TCRs from VKHdisease.It was also difficult to establish human regulatory dendritic cell specific to antigens for VKH disease.We studied the potential antigen presenting cells in intraocular tissues. There were several kind of cells that can uptake peptide antigens in intraocular tissues. These cells were divided into 3 to 4 groups.These cell groups had different cell surface markers and may play different functions. In the choroidal tissues, these cells may function as APCs stimulating the T cells, while in the retina, these cells may function as APCs regulating the T cells/
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cytotoxity of TCLs and TCC from aqueous humors and/or CSF with acute and fresh stage of VKH disease
VKH 病急性期和新鲜期房水和/或脑脊液中 TCL 和 TCC 的细胞毒性
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者: [Ando A, Kaneko S, Kiriyama N, Unezaki S, Okuda-Ashitaka E, Okumura T, Nishimura T, Matsumura M, Ito S., Kunihiko Yamaki]
通讯作者: Kunihiko Yamaki
国内基金
海外基金
高效Mage转座系统赋能KRAS G12D突变结直肠癌新型TCR-T疗法开发临床前研究
双靶向CAR-TCR-T疗法克服小细胞肺癌肿瘤异质性的机制探索
  • 批准号:
    JCZRLH202601115
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
Piezo1驱动的人工合成TCR-T精准靶向肝癌的治疗研究
  • 批准号:
    2026JJ60274
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    肖潺潺
  • 依托单位:
靶向PIK3CA突变的TCR-TCE NV制备及其在妊娠乳腺癌治疗中的研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    李罗
  • 依托单位: